अभी पंजीकरण करें

लॉग इन करें

पासवर्ड खो गया

आपका पासवर्ड खो गया है? कृपया अपना पूरा ईमेल दर्ज करें. आपको एक लिंक प्राप्त होगा और आप ईमेल के माध्यम से एक नया पासवर्ड बनाएंगे.

पोस्ट जोड़ें

पोस्ट जोड़ने के लिए आपको लॉगिन करना होगा .

प्रश्न जोड़ें

प्रश्न पूछने के लिए आपको लॉगिन करना होगा.

लॉग इन करें

अभी पंजीकरण करें

स्कॉलरसार्क.कॉम में आपका स्वागत है! आपका पंजीकरण आपको इस प्लेटफॉर्म की अधिक सुविधाओं का उपयोग करने की अनुमति देगा. आप सवाल पूछ सकते हैं, योगदान दें या उत्तर दें, अन्य उपयोगकर्ताओं के प्रोफ़ाइल देखें और बहुत कुछ. अभी पंजीकरण करें!

Biopharm Carrick therapeutics licenses targeted ovarian cancer drug from BTG

Dublin, Ireland-based biopharma Carrick Therapeutics has licensed exclusive global rights to develop and commercialise BTG’s targeted ovarian cancer drug BTG945.

The investigational drug, a combination of the targeting folate receptor α (FRα) and inhibiting thymidylate synthase, will now be referred to as CT900.


The small molecule compound – discovered by the Institute of Cancer Researchselectively enters cancer cells that over express folate receptor α (FRα) versus normal tissues and inhibits thymidylate synthase, leading to cell death.

Early clinical data is promisingin a Phase I study led by the ICR and The Royal Marsden NHS Foundation Trust, seven of ten women with advanced ovarian cancer who had the particular molecular marker for the drug responded to treatment, the firm noted.

“The efficacy results that we have seen so far for CT900 are very promising. The beauty of this drug is that it is targeted to the tumour cells, meaning there are fewer side-effects and making it a very promising treatment for women with ovarian cancer,” said Professor Paul Workman, chief executive and President of The ICR, लंडन, commenting on its potential.

Under the terms of the deal with BTG, financial details of which were not revealed, Carrick has gained exclusive worldwide development and commercialisation rights to CT900 and has already commenced preparations for pivotal studies.

The firm is also planning a clinical development programme in other cancers that express high levels of folate receptor alpha, it said.




के बारे में मैरी

उत्तर छोड़ दें